How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$17.9M | $1.8M | -$13.4M | -$3.1M | -$4.3M | |
| Operating Income | -$108.1M | -$117.2M | -$131.6M | -$31.4M | -$36.9M | |
| EBITDA | -$90.1M | -$119M | -$117.6M | -$28.3M | -$32.6M | |
| Diluted EPS | -$5.34 | -$5.31 | -$5.24 | -$1.58 | -$1.21 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $110.1M | $225.7M | $169.3M | $68.8M | $88.9M | |
| Total Assets | $170.9M | $248.1M | $189.8M | $93.1M | $110.5M | |
| Current Liabilities | $33.8M | $28.4M | $31.4M | $30.9M | $49.5M | |
| Total Liabilities | $54M | $36.1M | $45.8M | $39M | $57.6M | |
| Total Equity | $116.9M | $212.1M | $144M | $54M | $52.9M | |
| Total Debt | $8.3M | $1.5M | $94K | $7M | $6.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$89.9M | -$105.9M | -$98.6M | -$22.5M | -$32.4M | |
| Cash From Investing | -$655K | -$1.7M | $136.3K | -$109K | -$240.4K | |
| Cash From Financing | $6.7M | -$277K | $118.3M | $7K | -$325.6K | |
| Free Cash Flow | -$90.2M | -$108.7M | -$98.7M | -$22.9M | -$32.5M | |
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Chatillon, France.
In the current month, DBVT has received 4 Buy ratings 0 Hold ratings, and 1 Sell ratings. The DBVT average analyst price target in the past 3 months is $40.29.
According to analysts, the consensus estimate is that DBV Technologies SA share price will rise to $40.29 per share over the next 12 months.
Analysts are divided on their view about DBV Technologies SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that DBV Technologies SA is a Sell and believe this share price will drop from its current level to $8.19.
The price target for DBV Technologies SA over the next 1-year time period is forecast to be $40.29 according to 5 Wall Street analysts, 4 of them rate the stock a Buy, 1 rates the stock a Sell, and 0 analysts rate the stock a Hold.
According to Wall Street analysts, the consensus rating for DBV Technologies SA is a Buy. 4 of 5 analysts rate the stock a Buy at this time.
You can purchase shares of DBV Technologies SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase DBV Technologies SA shares.
DBV Technologies SA was last trading at $21.48 per share. This represents the most recent stock quote for DBV Technologies SA. Yesterday, DBV Technologies SA closed at $21.46 per share.
In order to purchase DBV Technologies SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
Operated up to now as a private business, SpaceX will…
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Market Cap: $4.2T
P/E Ratio: 59x
Market Cap: $4.1T
P/E Ratio: 37x
Market Cap: $4T
P/E Ratio: 41x
Silicon Laboratories, Inc. [SLAB] is up 0.91% over the past day.
Enphase Energy, Inc. [ENPH] is down 8.53% over the past day.
Mercury Systems, Inc. [MRCY] is up 2.61% over the past day.